Kenneth Bate, a director at Madrigal Pharmaceuticals ($MDGL), sold shares on the open market 17 times over the past year, totaling about $11.7 million. His most recent sale occurred on November 5, 2025. These sales rank him 1010th among 11,678 insiders by total value sold, above the average of $8.6 million across about 6 transactions per insider. Bate made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 23, 2026 | Astria Therapeutics, Inc. | $ATXS | BATE KENNETH | Not found | D | Stock Option (Right to Buy) | 14100 | $0.00 | 0.0000 | 58,005,928 | 100.00% | 0.02% |
| Jan. 23, 2026 | Astria Therapeutics, Inc. | $ATXS | BATE KENNETH | Not found | D | Stock Option (Right to Buy) | 26550 | $0.00 | 0.0000 | 58,005,928 | 100.00% | 0.05% |
| Jan. 23, 2026 | Astria Therapeutics, Inc. | $ATXS | BATE KENNETH | Not found | D | Stock Option (Right to Buy) | 16666 | $0.00 | 0.0000 | 58,005,928 | 100.00% | 0.03% |
| Jan. 23, 2026 | Astria Therapeutics, Inc. | $ATXS | BATE KENNETH | Not found | D | Stock Option (Right to Buy) | 8333 | $0.00 | 0.0000 | 58,005,928 | 100.00% | 0.01% |
| Jan. 23, 2026 | Astria Therapeutics, Inc. | $ATXS | BATE KENNETH | Not found | D | Stock Option (Right to Buy) | 14100 | $0.00 | 0.0000 | 58,005,928 | 100.00% | 0.02% |
| Nov. 5, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | M | Common Stock | 10000 | $303.79 | 18,097.0000 | 22,711,420 | 123.50% | 0.04% |
| Nov. 5, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | S | Common Stock | 2775 | $487.49 | 4,286.0000 | 22,711,420 | 39.30% | 0.01% |
| Nov. 5, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | S | Common Stock | 827 | $486.73 | 7,061.0000 | 22,711,420 | 10.48% | 0.00% |
| Nov. 5, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | S | Common Stock | 1008 | $485.54 | 7,888.0000 | 22,711,420 | 11.33% | 0.00% |
| Nov. 5, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | S | Common Stock | 1931 | $484.78 | 8,896.0000 | 22,711,420 | 17.84% | 0.01% |
| Nov. 5, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | S | Common Stock | 2069 | $483.41 | 10,827.0000 | 22,711,420 | 16.04% | 0.01% |
| Nov. 5, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | S | Common Stock | 1284 | $482.41 | 12,896.0000 | 22,711,420 | 9.06% | 0.01% |
| Nov. 5, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | S | Common Stock | 3259 | $481.13 | 14,180.0000 | 22,711,420 | 18.69% | 0.01% |
| Nov. 5, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | S | Common Stock | 1763 | $480.24 | 17,439.0000 | 22,711,420 | 9.18% | 0.01% |
| Nov. 5, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | M | Common Stock | 1105 | $280.04 | 19,202.0000 | 22,711,420 | 6.11% | 0.00% |
| Nov. 5, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | M | Common Stock | 5470 | $9.45 | 8,097.0000 | 22,711,420 | 208.22% | 0.02% |
| Nov. 5, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | M | Stock Option (Right to Buy) | 1105 | $0.00 | 0.0000 | 22,711,420 | 100.00% | 0.00% |
| Nov. 5, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | M | Stock Option (Right to Buy) | 10000 | $0.00 | 0.0000 | 22,711,420 | 100.00% | 0.04% |
| Nov. 5, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | M | Stock Option (Right to Buy) | 5470 | $0.00 | 0.0000 | 22,711,420 | 100.00% | 0.02% |
| Nov. 5, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | S | Common Stock | 30 | $490.98 | 2,627.0000 | 22,711,420 | 1.13% | 0.00% |
| Nov. 5, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | S | Common Stock | 933 | $489.95 | 2,657.0000 | 22,711,420 | 25.99% | 0.00% |
| Nov. 5, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | S | Common Stock | 696 | $489.09 | 3,590.0000 | 22,711,420 | 16.24% | 0.00% |
| Aug. 15, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | S | Common Stock | 600 | $366.14 | 4,627.0000 | 22,080,246 | 11.48% | 0.00% |
| Aug. 15, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | S | Common Stock | 1104 | $367.63 | 3,523.0000 | 22,080,246 | 23.86% | 0.00% |
| Aug. 15, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | S | Common Stock | 896 | $368.56 | 2,627.0000 | 22,080,246 | 25.43% | 0.00% |
| Aug. 15, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | M | Stock Option (Right to Buy) | 10000 | $0.00 | 0.0000 | 22,080,246 | 100.00% | 0.05% |
| Aug. 15, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | S | Common Stock | 2317 | $363.41 | 10,310.0000 | 22,080,246 | 18.35% | 0.01% |
| Aug. 15, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | M | Common Stock | 10000 | $16.46 | 12,627.0000 | 22,080,246 | 380.66% | 0.05% |
| Aug. 15, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | S | Common Stock | 2567 | $365.33 | 5,227.0000 | 22,080,246 | 32.94% | 0.01% |
| Aug. 15, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | S | Common Stock | 2516 | $364.24 | 7,794.0000 | 22,080,246 | 24.40% | 0.01% |
| June 20, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | A | Common Stock | 715 | $0.00 | 2,627.0000 | 22,080,246 | 37.40% | 0.00% |
| June 20, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | A | Stock Option (Right to Buy) | 1290 | $0.00 | 1,290.0000 | 22,080,246 | 9999.99% | 0.01% |
| June 11, 2025 | Astria Therapeutics, Inc. | $ATXS | BATE KENNETH | Director | A | Stock Option (Right to Buy) | 26550 | $0.00 | 26,550.0000 | 58,005,312 | 9999.99% | 0.05% |
| Feb. 27, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | M | Common Stock | 9470 | $65.06 | 17,382.0000 | 22,080,246 | 119.69% | 0.04% |
| Feb. 27, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | M | Common Stock | 6000 | $111.06 | 7,912.0000 | 22,080,246 | 313.81% | 0.03% |
| Feb. 27, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | M | Stock Option (Right to Buy) | 4530 | $0.00 | 5,470.0000 | 22,080,246 | 45.30% | 0.02% |
| Feb. 27, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | M | Stock Option (Right to Buy) | 9470 | $0.00 | 0.0000 | 22,080,246 | 100.00% | 0.04% |
| Feb. 27, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | M | Stock Option (Right to Buy) | 6000 | $0.00 | 0.0000 | 22,080,246 | 100.00% | 0.03% |
| Feb. 27, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | S | Common Stock | 216 | $360.07 | 1,912.0000 | 22,080,246 | 10.15% | 0.00% |
| Feb. 27, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | S | Common Stock | 2024 | $359.21 | 2,128.0000 | 22,080,246 | 48.75% | 0.01% |
| Feb. 27, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | S | Common Stock | 3548 | $358.33 | 4,152.0000 | 22,080,246 | 46.08% | 0.02% |
| Feb. 27, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | S | Common Stock | 2038 | $357.27 | 7,700.0000 | 22,080,246 | 20.93% | 0.01% |
| Feb. 27, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | S | Common Stock | 2791 | $356.51 | 9,738.0000 | 22,080,246 | 22.28% | 0.01% |
| Feb. 27, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | S | Common Stock | 8545 | $355.08 | 12,529.0000 | 22,080,246 | 40.55% | 0.04% |
| Feb. 27, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | S | Common Stock | 238 | $353.83 | 21,074.0000 | 22,080,246 | 1.12% | 0.00% |
| Feb. 27, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | S | Common Stock | 500 | $351.99 | 21,312.0000 | 22,080,246 | 2.29% | 0.00% |
| Feb. 27, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | S | Common Stock | 100 | $351.01 | 21,812.0000 | 22,080,246 | 0.46% | 0.00% |
| Feb. 27, 2025 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | M | Common Stock | 4530 | $9.45 | 21,912.0000 | 22,080,246 | 26.06% | 0.02% |
| June 25, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Not found | A | Stock Option (Right to Buy) | 1105 | $0.00 | 1,105.0000 | 0 | 9999.99% | 0.00% |
| June 25, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Not found | A | Common Stock | 714 | $0.00 | 1,912.0000 | 0 | 59.60% | 0.00% |
| June 5, 2024 | Astria Therapeutics, Inc. | $ATXS | BATE KENNETH | Director | A | Stock Option (Right to Buy) | 14100 | $0.00 | 14,100.0000 | 52,294,765 | 9999.99% | 0.03% |
| April 1, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | M | Stock Option (Right to Buy) | 10000 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| April 1, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | M | Stock Option (Right to Buy) | 1277 | $0.00 | 11,212.0000 | 0 | 10.23% | 0.00% |
| April 2, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | M | Stock Option (Right to Buy) | 11212 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| April 1, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | S | Common Stock | 7411 | $256.49 | 8,366.0000 | 0 | 46.97% | 0.00% |
| April 1, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | M | Common Stock | 1277 | $105.08 | 22,475.0000 | 0 | 6.02% | 0.00% |
| April 1, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | M | Common Stock | 10000 | $100.45 | 21,198.0000 | 0 | 89.30% | 0.00% |
| April 1, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | M | Common Stock | 10000 | $9.45 | 11,198.0000 | 0 | 834.72% | 0.00% |
| April 1, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | S | Common Stock | 6698 | $255.62 | 15,777.0000 | 0 | 29.80% | 0.00% |
| April 1, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | S | Common Stock | 2790 | $257.33 | 5,576.0000 | 0 | 33.35% | 0.00% |
| April 1, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | S | Common Stock | 2104 | $258.24 | 3,472.0000 | 0 | 37.73% | 0.00% |
| April 1, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | S | Common Stock | 200 | $259.13 | 3,272.0000 | 0 | 5.76% | 0.00% |
| April 1, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | S | Common Stock | 841 | $262.18 | 2,431.0000 | 0 | 25.70% | 0.00% |
| April 1, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | S | Common Stock | 143 | $263.08 | 2,288.0000 | 0 | 5.88% | 0.00% |
| April 1, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | S | Common Stock | 116 | $264.73 | 2,172.0000 | 0 | 5.07% | 0.00% |
| April 1, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | S | Common Stock | 700 | $265.36 | 1,472.0000 | 0 | 32.23% | 0.00% |
| April 1, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | S | Common Stock | 274 | $266.91 | 1,198.0000 | 0 | 18.61% | 0.00% |
| April 2, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | M | Common Stock | 11212 | $105.08 | 12,410.0000 | 0 | 935.89% | 0.00% |
| April 2, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | S | Common Stock | 1217 | $243.28 | 11,193.0000 | 0 | 9.81% | 0.00% |
| April 2, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | S | Common Stock | 7048 | $244.27 | 4,145.0000 | 0 | 62.97% | 0.00% |
| April 2, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | S | Common Stock | 2080 | $244.97 | 2,065.0000 | 0 | 50.18% | 0.00% |
| April 2, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | S | Common Stock | 567 | $246.20 | 1,498.0000 | 0 | 27.46% | 0.00% |
| April 2, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | S | Common Stock | 100 | $246.88 | 1,398.0000 | 0 | 6.68% | 0.00% |
| April 2, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | S | Common Stock | 193 | $248.49 | 1,205.0000 | 0 | 13.81% | 0.00% |
| April 2, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | S | Common Stock | 7 | $249.05 | 1,198.0000 | 0 | 0.58% | 0.00% |
| April 1, 2024 | MADRIGAL PHARMACEUTICALS, INC. | $MDGL | BATE KENNETH | Director | M | Stock Option (Right to Buy) | 10000 | $0.00 | 10,000.0000 | 0 | 50.00% | 0.00% |